Mismatch repair (MMR) status alone is insufficient to guide the use of PD-(L)1 monotherapy in patients with endometrial cancer. Additional biomarkers, including tumor mutational burden and combined positive score, may help to identify patients with MMR-proficient tumors with a high probability of benefit from PD-(L)1 monotherapy, and those with MMR-deficient tumors who might require combination strategies.

See related article by Oaknin et al., p. 4564

©2023 American Association for Cancer Research
2023
American Association for Cancer Research
You do not currently have access to this content.